# Softgel Capsule Market

> Softgel Capsule Market Research Report By Application (Nutraceuticals, Pharmaceuticals, Cosmetics, Vitamins, Dietary Supplements), By Ingredients (Gelatin, Fish Gelatin, Vegetable Gelatin, Active Ingredients, Colorants), By Formulation (Single Phase, Multi-Phase, Emulsified, Suspended, Gelled), By Distribution Channel (Online Retail, Pharmacies, Health Stores, Supermarkets, Direct Sales) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2026-2035
- **CAGR:** 6.3%
- **2025:** USD 9.48 Billion
- **2035:** USD 17.39 Billion
- **Key Players:** Catalent, Inc., Aenova Group, Procaps Group, Sirio Pharma, Captek Softgel International, ACG Group, EuroCaps Ltd., Fuji Capsule Co., Ltd.

**Report ID:** MRFR/Pharma/5998-CR · **Pages:** 101 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** August 25, 2026

**URL:** https://www.marketresearchfuture.com/reports/softgel-capsule-market-7467

---

## Market Summary

According to Market Research Future analysis, the Softgel Capsule Market Size was valued at USD 4.619 Billion in 2024 & the market is projected to grow from USD 4.882 Billion in 2025 to USD 8.499 Billion by 2035, registering a CAGR of 5.7% during the forecast period 2025–2035. Rising global focus on preventive healthcare and nutritional supplementation is significantly driving the softgel capsule market, as consumers increasingly prefer easy-to-consume, highly bioavailable dosage forms that enhance absorption efficiency and support long-term wellness and chronic disease management across diverse populations.
 
According to WHO, over 1.9 billion adults were overweight in 2022, increasing demand for nutraceuticals, while CDC reports 6 in 10 adults have chronic diseases, boosting supplement usage; this growing disease burden positively supports softgel adoption globally.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Self-care and preventive supplement spending | +1.3 pp | Global | Medium-term (2–4 yr) | [9] |
| Shift to plant-based and clean-label shells | +0.9 pp | Europe, North America | Medium-term (2–4 yr) | [3] |
| Bioavailability gains for poorly soluble APIs | +0.8 pp | Global | Long-term (≥4 yr) | [10] |
| CDMO capacity build-out and outsourcing | +0.7 pp | North America, Europe | Short-term (≤2 yr) | [5] |
| Asia-Pacific manufacturing localisation | +0.6 pp | Asia-Pacific | Medium-term (2–4 yr) | [1] |
| Ageing populations and chronic disease load | +0.5 pp | Japan, Europe, North America | Long-term (≥4 yr) | [11] |
| Direct-to-consumer and e-commerce channels | +0.4 pp | Global | Short-term (≤2 yr) | [12] |

### Preventive Health Spending Reshapes Volume Demand

Self-medication by consumers is no longer a specialty. According to a 2024 poll by the Council for Responsible Nutrition, softgels are the most popular form of oil-based active ingredients, and 75% of American people reported using a dietary supplement in the previous year [[9]](https://crnusa.org). This preference is important from a business standpoint because a softgel is usually 30–45% more expensive than a comparable two-piece hard capsule. As a result, changes in the format mix directly increase the value of the softgel capsule market.

### Non-Animal Shells Move From Pilot to Production

Pressure from procurement and regulations has accomplished what consumer demand alone was unable to achieve. Pullulan and hypromellose shells increased from less than 12% of new product releases in 2021 to over 26% in 2025 due to the European Food Safety Authority's stricter regulations on animal-derived processing aids and retailer vegan certification requirements [[3]](https://evonik.com)[[13]](https://efsa.europa.eu). The friction point is capital expenditure; it costs USD 1.8–2.6 million per line to adapt a rotary die line for plant-based ribbon [[5]](https://investor.catalent.com).

### Bioavailability Economics for Lipid Formulations

Roughly 40% of new chemical entities in development are practically insoluble in water, and self-emulsifying drug delivery systems encapsulated in softgel form remain among the most reliable fixes [[10]](https://usp.org). Published bioequivalence work shows lipid-filled softgels delivering 1.6–2.4× the plasma exposure of dry-blend tablets for selected lipophilic actives, which shortens clinical timelines and justifies the higher unit cost [[14]](https://lonza.com).

### Contract Manufacturing Consolidation

Brand owners are exiting in-house encapsulation. Between 2023 and 2025, at least eleven mid-size supplement brands divested or shuttered captive softgel lines in favour of contract supply, and the top ten global encapsulators added an estimated 14 billion units of annual nameplate capacity over the same window [[5]](https://investor.catalent.com)[[15]](https://sciencepharma.com).

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Bovine and porcine gelatin price volatility | −0.6 pp | Global | Short-term (≤2 yr) | [7] |
| Competition from gummy and stick-pack formats | −0.5 pp | North America, Europe | Medium-term (2–4 yr) | [12] |
| Religious and dietary restrictions on animal shells | −0.4 pp | MEA, South Asia | Long-term (≥4 yr) | [13] |
| Capital intensity and encapsulation line lead times | −0.3 pp | Global | Medium-term (2–4 yr) | [5] |
| Tightening supplement claim enforcement | −0.3 pp | North America, Europe | Short-term (≤2 yr) | [2] |

### Raw Material Exposure Remains Unhedged

Pricing for gelatin monitors the supply of hides and bones, which in turn monitors the cycles of cattle slaughter. Few encapsulators maintain forward cover for more than two quarters, and type B bovine gelatin contract prices fluctuated within a 22% range between early 2023 and late 2025 [[7]](https://darlingii.com). Since shell material makes up 18–24% of the final cost of softgel, volatility nearly immediately affects gross margin.

### Format Substitution in Consumer Health

By 2025, gummies accounted for about 19% of vitamin dollar sales in the United States, primarily from adult multivitamin and single-nutrient categories where softgels had previously held a dominant position [[12]](https://newhope.com). The softgel share in fish oil, vitamin D, and CoQ10 is preserved because gummies cannot carry high-dose oil loads without sugar and stability penalties.

### Certification Friction in Restricted Markets

Halal and kosher certification for porcine-free supply chains adds 4–7 months to qualification and requires segregated storage, a real barrier for exporters targeting Gulf and Southeast Asian buyers [[13]](https://efsa.europa.eu).

## Opportunities

## Softgel Capsule Market Opportunities

### Enteric and Delayed-Release Softgels

Cardiology, gastrointestinal, and probiotic sectors that were previously closed to the softgel capsule market are now open thanks to enteric-coated and intrinsically enteric shells. The format is feasible for higher-margin prescription work since plasticizer-free enteric dispersions eliminate a typical extractables issue and reduce coating cycle time by about 30% [[3]](https://evonik.com).

### Emerging-Market Domestic Supply

Despite robust domestic supply chains for fish oil and API, India, Indonesia, and Brazil collectively import a significant portion of completed softgels. An estimated USD 0.9 billion in imports might be replaced by domestic encapsulation build-out supported by incentive programs by 2032 [[1]](https://pharmaceuticals.gov.in).

b

### Cosmeceutical and Topical Softgels

Single-dose twist-off softgels for serums and hair oils are scaling fast in South Korea and Japan, where premium skincare buyers value dose precision and oxidation control. Unit economics beat airless pumps below 1.5 mL fill volumes [[16]](https://procapsgroup.com).

### Data-Enabled Manufacturing Services

Vision-based seam inspection and inline weight variation analytics generate batch datasets that encapsulators are beginning to sell back as release-support packages, a genuine new revenue line rather than a cost centre. Early adopters report scrap reduction of 1.8–2.5 percentage points [[17]](https://ispe.org).

### Marine and Algal Oil Premiumisation

Algal-sourced fills let brands market omega-3 softgel supplements without fish sourcing concerns, commanding a 40–60% retail premium in Western Europe [[18]](https://goedomega3.com).

## Future Outlook

## Softgel Capsule Market Future Outlook

### Continuous Manufacturing and Inline Release

Batch encapsulation is giving way to semi-continuous lines with inline near-infrared assay and automated seam inspection. Sites running these configurations report 15–20% higher effective uptime, and regulators have signalled comfort with real-time release for well-characterised fills [[17]](https://ispe.org). Expect a fifth of Softgel Capsule Market volume to run on such lines by 2033.

### Biologics and Peptide Encapsulation

Oral peptide delivery has moved from theory to approved product. Permeation-enhanced lipid vehicles encapsulated in enteric softgels are now in late-stage trials for at least six peptide candidates, a category that barely existed in 2020 [[10]](https://usp.org).

### Sustainability Accounting

Gelatin's carbon footprint sits materially above plant polymers on a per-kilogram basis, and Corporate Sustainability Reporting Directive disclosure obligations are pulling this into procurement scorecards across Europe [[8]](https://ec.europa.eu). Shell selection is becoming an ESG decision, not just a formulation one.

### Supply Chain Regionalisation

Pandemic-era single-sourcing lessons have stuck. Dual-region qualification is becoming standard for pharmaceutical customers of the Softgel Capsule Market, adding validation cost but reducing the tail risk that drove 2021 shortages [[15]](https://sciencepharma.com).

## Segment Insights

## Softgel Capsule Market Segmentation

Segmentation of the Softgel Capsule Market follows shell chemistry and end application, the two dimensions that determine both plant configuration and pricing power.

### By Shell Source

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Gelatin (Animal-Based) | 76.0% share (2025) | Cost, seam reliability, established validation |
| Non-Animal-Based | 7.4% CAGR (2026–2035) | Vegan, halal, and kosher certification demand |

Gelatin retains its grip on the Softgel Capsule Market for sound engineering reasons: predictable gel strength, fast set, and decades of stability data. Non-animal shells win on access, not performance — they unlock retail listings and export markets that increasingly screen for animal-derived inputs. The crossover point for new product launches is likely around 2031.

### By Application

| Segment | Key Metric | Primary Demand Driver |
| --- | --- | --- |
| Pharmaceuticals | 55.8% share (2025) | Lipid-based delivery for insoluble APIs |
| Nutraceuticals and Dietary Supplements | 8.1% CAGR (2026–2035) | Preventive health and D2C retail |
| Cosmetics and Personal Care | USD 0.87 Billion (2025) | Single-dose serum and oil formats |
| Other Applications | 4.6% share (2025) | Veterinary and specialty industrial fills |

Pharmaceutical demand within the Softgel Capsule Market is anchored by [analgesics](https://www.marketresearchfuture.com/reports/analgesics-market-19195), hormone therapies, and vitamin D analogues, where liquid-filled soft capsules deliver dose uniformity that dry blends struggle to match. Nutraceuticals grow faster but at lower unit value; the interesting margin story sits at the intersection, in prescription-grade omega-3 and medical food products that borrow pharmaceutical quality systems and supplement channel economics.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Key Metric | Primary Investment Themes |
| --- | --- | --- |
| North America | 30.9% share (2025) | Vegan shell retrofits, prescription CDMO capacity |
| Europe | USD 2.60 Billion (2025) | Clean-label reformulation, enteric lines |
| Asia-Pacific | 8.2% CAGR (2026–2035) | Greenfield encapsulation, export finishing |
| South America | USD 0.61 Billion (2025) | Local fill-finish, supplement retail growth |
| Middle East & Africa | 5.5% share (2025) | Halal-certified supply, import substitution |
| Total | USD 9.48 Billion (2025) | — |

Regional performance across the Softgel Capsule Market reflects three distinct dynamics: mature-market premiumisation, Asia-Pacific capacity localisation, and import-dependent frontier demand.

### North America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| US | 82.4% of regional revenue | Supplement retail density and cGMP enforcement |
| Canada | USD 0.29 Billion (2025) | Natural Health Product licensing pipeline |
| Mexico | 6.9% CAGR (2026–2035) | Nearshoring of finished dosage manufacturing |

North America's lead in the Softgel Capsule Market rests on regulatory infrastructure as much as consumption. The Food and Drug Administration issued more than 500 dietary supplement warning letters between 2022 and 2025, accelerating brand migration to audited contract sites [[2]](https://fda.gov). Mexico's role is changing fastest — USMCA rules of origin and shorter logistics chains have drawn at least four new encapsulation lines to Jalisco and Nuevo León since 2023 [[15]](https://sciencepharma.com).

### Europe

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Germany | 23.1% of regional revenue | Pharmaceutical CDMO concentration |
| UK | USD 0.41 Billion (2025) | Post-Brexit domestic supply rebuild |
| France | 14.6% of regional revenue | Cosmeceutical and marine oil demand |
| Italy | USD 0.31 Billion (2025) | Nutraceutical export base |
| Spain | 6.4% CAGR (2026–2035) | Private-label supplement manufacturing |
| Nordic Countries | USD 0.19 Billion (2025) | Cod liver and algal oil heritage brands |
| Russia | 4.1% of regional revenue | Import substitution programmes |
| Rest of Europe | 5.8% CAGR (2026–2035) | Central European contract capacity |

Europe's growth is qualitative rather than volumetric. Regulation 2023/2854 on food contact and processing transparency, alongside national vegan labelling schemes, has forced reformulation across roughly a third of the region's supplement SKUs [[8]](https://ec.europa.eu). Germany remains the technical centre of gravity, hosting three of the ten largest encapsulation sites globally.

### Asia-Pacific

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| China | 34.8% of regional revenue | Domestic health food registration reform |
| India | 9.1% CAGR (2026–2035) | PLI-backed capacity and export contracts |
| Japan | USD 0.52 Billion (2025) | FOSHU-approved functional formats |
| South Korea | 11.2% of regional revenue | Cosmeceutical single-dose formats |
| ASEAN | USD 0.31 Billion (2025) | Halal-certified regional hub ambitions |
| Rest of Asia-Pacific | 7.4% CAGR (2026–2035) | Rising middle-class supplement uptake |

Asia-Pacific is where the Softgel Capsule Market adds the most absolute capacity this decade. China's revised health food filing system shortened approval timelines for well-characterised nutrients from roughly 18 months to under 9 months, unlocking a launch backlog [[19]](https://samr.gov.cn). India's advantage is different — a deep gelatin supply base, competitive conversion cost, and regulatory recognition in over 90 export destinations.

### South America

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Brazil | 61.5% of regional revenue | ANVISA supplement framework maturation |
| Argentina | USD 0.09 Billion (2025) | Domestic pharmaceutical fill-finish |
| Rest of South America | 6.7% CAGR (2026–2035) | Andean retail pharmacy expansion |

Brazil's 2022 consolidation of supplement categories under a single ANVISA framework removed years of classification ambiguity, and registrations have risen sharply since [[20]](https://gov.br/anvisa). Regional encapsulators still import most shell-grade gelatin, which caps margin.

### Middle East & Africa

| Country | Key Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 29.4% of regional revenue | Vision 2030 local manufacturing targets |
| UAE | USD 0.11 Billion (2025) | Re-export hub and free-zone logistics |
| South Africa | 8.3% CAGR (2026–2035) | SAHPRA complementary medicine registration |
| Egypt | 12.7% of regional revenue | Currency-driven import substitution |
| Rest of MEA | USD 0.09 Billion (2025) | Aid-funded pharmaceutical procurement |

Saudi Arabia's localisation targets under Vision 2030 require a rising share of pharmaceutical procurement from domestic sites, and two softgel facilities have broken ground near Riyadh since 2024 [[21]](https://sfda.gov.sa). Halal certification is the entry ticket across the region, favouring non-animal and bovine-only supply chains.

## Competitive Benchmarking

## Competitive Benchmarking

Concentration in the Softgel Capsule Market is moderate. Analyst estimates place the Herfindahl-Hirschman Index between 620 and 780, with the top five players controlling roughly 33–38% of global revenue. The long tail is substantial — several hundred regional encapsulators serve local supplement brands — but capability in enteric, high-potency, and non-animal shells concentrates rapidly among the top tier.

| Company | Est. Revenue Share Range | Key Offerings for Softgel Capsule Market | Strategic Positioning |
| --- | --- | --- | --- |
| Catalent, Inc. | ~10–13% | OptiShell, OptiGel, enteric and vegetarian shells | Technology leader; broadest pharmaceutical validation base |
| Aenova Group | ~6–9% | SwissCaps softgel platform, high-potency fills | European pharmaceutical CDMO scale |
| Procaps Group | ~5–7% | Softigel contract encapsulation, Unigel | Latin American leader with U.S. export reach |
| Sirio Pharma | ~4–6% | Nutraceutical softgels, plant-based shells | Fastest-scaling Asia-Pacific supplement CDMO |
| Captek Softgel International | ~3–5% | Premium supplement softgels, custom fills | U.S. private-label specialist |
| ACG Group | ~3–4% | Encapsulation equipment, shell polymers | Vertically integrated equipment-to-shell supplier |
| EuroCaps Ltd. | ~2–4% | High-volume supplement softgels | UK and EU volume manufacturer |
| Fuji Capsule Co., Ltd. | ~2–3% | Specialty and cosmetic softgels | Japanese precision and small-batch niche |
| Strides Pharma Science | ~2–3% | Regulated-market pharmaceutical softgels | India-based, multi-market filings |
| Thermo Fisher Scientific (Patheon) | ~2–3% | Integrated softgel development and commercial supply | Full-service pharmaceutical CDMO bundling |
| Baotai Pharmaceutical | ~1–3% | Gelatin and plant-based shell manufacturing | China domestic supply scale |

## Recent News & Developments

## Recent News & Developments

- Catalent (July 2024): Completed a capacity expansion for vegetarian softgel manufacturing at its European network, targeting clean-label supplement customers [[5]](https://investor.catalent.com)
- Sirio Pharma (January 2025): Opened a new plant-based encapsulation facility in Guangdong, adding roughly 3 billion units of annual nameplate capacity [[15]](https://sciencepharma.com)

- Procaps Group (November 2023): Announced a multi-year supply agreement with a North American supplement brand covering high-dose marine oil fills [[16]](https://procapsgroup.com)
- ANVISA (April 2024): Streamlined registration pathways for imported supplement dosage forms, shortening Brazilian market entry timelines [[20]](https://gov.br/anvisa)

## Report Scope

| Parameter | Detail |
| --- | --- |
| Market Scope | Global Softgel Capsule Market by shell source, application, and geography |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR | 6.3% (2026–2035) |
| Market Size Checkpoints | USD 9.48 Billion (2025); USD 10.04 Billion (2026); USD 17.39 Billion (2035) |
| Fastest Growing Segments | Non-animal-based shells (7.4% CAGR); Nutraceuticals and dietary supplements (8.1% CAGR); Asia-Pacific (8.2% CAGR) |
| Companies Profiled | 11 major encapsulators and integrated suppliers |
| Valuation Currency | USD Billion |

## Frequently Asked Questions

**Q: What due diligence should a buyer complete before signing a softgel contract manufacturing agreement?**
A: Audit line-level traceability documentation for animal-derived inputs, confirm nitrogen-flush packaging capability, and request three years of batch-rejection data. Contracts lacking a defined technology-transfer exit clause typically add six months to any future supplier switch. [14]

**Q: How does the Softgel Capsule Market handle cross-linking risk in dissolution testing?**
A: Aldehyde-driven cross-linking can fail dissolution without affecting actual bioavailability. Regulators accept two-tier enzymatic testing when properly justified, and formulators increasingly specify low-aldehyde polyethylene glycol grades at the raw-material stage. [2]

**Q: Which cost lines move most when switching shells in the Softgel Capsule Market?**
A: Shell material cost rises roughly 25–40% moving from gelatin to plant polymers, though shorter drying-tunnel residence partially offsets throughput loss. Validation and stability re-testing dominate the first-year budget. [3]

**Q: Is contract capacity in the Softgel Capsule Market currently tight?**
A: High-potency and vegetarian lines are booked well ahead, while commodity gelatin capacity remains comparatively available. Buyers specifying non-animal shells should plan on nine to twelve-month qualification lead times. [15]

**Q: What packaging choices matter most for oxidation-sensitive fills?**
A: Aluminium-aluminium blisters outperform HDPE bottles on peroxide control. Nitrogen headspace flushing at fill, combined with desiccant inserts, extends usable shelf life by roughly one-third in accelerated stability studies. [18]

**Q: How should investors think about valuation multiples for encapsulators?**
A: Pure-play encapsulators generally trade below diversified contract development organisations because fill complexity is more replicable. Premiums attach to sites holding both regulated-drug and supplement approvals under one quality system. [16]

**Q: What integration challenges follow a softgel plant acquisition?**
A: Melt recipes and ribbon-spread settings rarely transfer cleanly between sites, even with identical equipment. Expect six to nine months of comparability work before a product can be reliably dual-sourced. [22]


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/softgel-capsule-market-7467*